Will the rollover be better?

Quote

Anonymous

Guest
It appears most of us will get rolled over in a few months but this company is very unstable from a financial standpoint. Look at the balance sheets and do the math, this company will be out of money this time next year without major uptake in Silenor sales!!!
 






Anonymous said:
It appears most of us will get rolled over in a few months but this company is very unstable from a financial standpoint. Look at the balance sheets and do the math, this company will be out of money this time next year without major uptake in Silenor sales!!!
Click to expand...

How can there feasibly be a rollover when Sllenor is getting killed with managed care and generic substitution? If Slienor goes OTC, the whole sales force is toast.
 






Sorry, this "rollover" is just a dangling carrot...Make everyone in the field feel good and secure, pound it out and squeeze as much blood as we can outta this turnip these last few months --- then BAM! Silenor goes OTC, no more sales force....just as planned. I hope I'm wrong - I kinda like it here, but I'm concerned...Any positive thoughts?
 






Anonymous said:
Sorry, this "rollover" is just a dangling carrot...Make everyone in the field feel good and secure, pound it out and squeeze as much blood as we can outta this turnip these last few months --- then BAM! Silenor goes OTC, no more sales force....just as planned. I hope I'm wrong - I kinda like it here, but I'm concerned...Any positive thoughts?
Click to expand...

I totally agree with your post. Most will get rolled in but this will be a very difficult place to work moving forward. I hope Silenor does go OTC within the next year so I can make a few bucks on the stock. Buy now!!
 






Anonymous said:
Sorry, this "rollover" is just a dangling carrot...Make everyone in the field feel good and secure, pound it out and squeeze as much blood as we can outta this turnip these last few months --- then BAM! Silenor goes OTC, no more sales force....just as planned. I hope I'm wrong - I kinda like it here, but I'm concerned...Any positive thoughts?
Click to expand...

This article hits the nail on the head. OTC is 5-7 years out and Somaxon will not be around by then.

BOSTON (TheStreet) -- Louis N. writes, "Adam, this was a week for sleeping pill news with Somaxon Pharmaceuticals(SOMX_) and Transcept Pharmaceuticals(TSPT_). I follow your tweets and you seem not to like either. Can you explain in more detail and tell me if there's anything positive going on?"

I'll begin with Somaxon because it's the worst of the two sleeping pill stocks. The commercial launch of Somaxon's Silenor is a bust. The company all but gave up on the prescription market this week when it announced the dissolution of the contract sales force agreement with Procter & Gamble(PG_) and the departure of its top marketing executive.

Somaxon could have pre-announced Silenor revenue for the third quarter if it wanted to send the message that the sleeping pill's performance was turning around for the better. The company chose not to do so, which sends the opposite message: Silenor sales are still in the crapper.

What Somaxon chose to do instead was to divert investor attention by once again raising the possibility of Silenor as an over-the-counter (no prescription required) sleep aid. Keep in mind that Somaxon and partner P&G have no commitment or agreed-upon regulatory plan from FDA that it would allow Silenor to go OTC. Somaxon merely claims that it "believes" there is an OTC path for the drug based on a meeting with FDA.

Be wary when you see a company roll out the word "believes" in press release related to FDA regulatory stuff. "Believes" is one of those lawyer-safe words that give companies an excuse when the promises they make blow up.

Regardless, Somaxon admits that it will take five to seven years (!!) to complete all the studies and paperwork necessary before FDA even makes an OTC decision on Silenor. Good luck and be patient because time is not on your side. In the meantime, an OTC sleep aid already exists -- it's called NyQuil.
 






Many new pharm companies start out like this...

Contract then roll-over to parent company, add new products, etc...

Also, there are a lot of companies (big name companies) finding new and beneficial uses for older compounds. Some make sense and some don't.

Most people realize that Silenor is a really good product when they think about how it benefits patients and not the fact that it is doxepin and has been around a long time.

There is no reason that Somaxon and Silenor cannot succeed in the industry...
 






Anonymous said:
Many new pharm companies start out like this...

Contract then roll-over to parent company, add new products, etc...

Also, there are a lot of companies (big name companies) finding new and beneficial uses for older compounds. Some make sense and some don't.

Most people realize that Silenor is a really good product when they think about how it benefits patients and not the fact that it is doxepin and has been around a long time.

There is no reason that Somaxon and Silenor cannot succeed in the industry...
Click to expand...

The one thing missing from this company is strong leadership. This company will be out of money by this time next year because they will blow a ton of money on DTC commercials that will do little for the bottom line. Just look at Lunesta, they spent 400 million on advertising on a product doing 400 million in sales. The same thing will happen here but with no fall back product to allow the company to survive.
 






If you listened to the conference call to analysts, they didn't say DTC as in television but more web based and individually focused.
You are correct though as mass marketing on TV is very expensive and wasteful.
 






Anonymous said:
Many new pharm companies start out like this...

Contract then roll-over to parent company, add new products, etc...

Also, there are a lot of companies (big name companies) finding new and beneficial uses for older compounds. Some make sense and some don't.

Most people realize that Silenor is a really good product when they think about how it benefits patients and not the fact that it is doxepin and has been around a long time.

There is no reason that Somaxon and Silenor cannot succeed in the industry...
Click to expand...

NO REASON??????Get your head out of your ass!! Just to name a few reasons,MC,crowded sleep market with proven winners,generics,etc. Do you get the picture yet?? Quit giving people false hope. Now you list the reasons?? you mention that Silenor can succeed. Your director of training has bailed already.
 






Anonymous said:
If you listened to the conference call to analysts, they didn't say DTC as in television but more web based and individually focused.
You are correct though as mass marketing on TV is very expensive and wasteful.
Click to expand...

Didn't have to listen to the call dumb ass because I sat next to the ad agency who was developing the Silenor commercial. The TV ad is already done so become better informed before you speak on a topic you know nothing about!!!
 






Not going to stoop to a name calling game but it will be a print DTC campaign. If you want to know what creature will be featured, I could give you that too. Look in Sunday newspapers and select magazine after the 1st of the year.
 






Anonymous said:
Not going to stoop to a name calling game but it will be a print DTC campaign. If you want to know what creature will be featured, I could give you that too. Look in Sunday newspapers and select magazine after the 1st of the year.
Click to expand...

I think you are wrong so lets just wait and see. The new TV commercial will be rolled out at the meeting in January, assuming you will make the cut ?
 






Anonymous said:
Not going to stoop to a name calling game but it will be a print DTC campaign. If you want to know what creature will be featured, I could give you that too. Look in Sunday newspapers and select magazine after the 1st of the year.
Click to expand...

If this is true anyone and everyone in marketing should be fired. I don't work in pharma marketing but print ads are worthless. I do realize you guys are trying to hit the senior market, which would be more likely to be reading print, but how you're not buying late night cable units which even the most banal of snake oil dick enlargers can afford to target people who can't fall asleep has been beyond me. I hope you have some kind of DTC TV advertising lined up with a modest spend in the late night as a stockholder to tie things over until OTC comes through.
 






Anonymous said:
If this is true anyone and everyone in marketing should be fired. I don't work in pharma marketing but print ads are worthless. I do realize you guys are trying to hit the senior market, which would be more likely to be reading print, but how you're not buying late night cable units which even the most banal of snake oil dick enlargers can afford to target people who can't fall asleep has been beyond me. I hope you have some kind of DTC TV advertising lined up with a modest spend in the late night as a stockholder to tie things over until OTC comes through.
Click to expand...

The OTC story was just a last ditch effort to drive the stock price up. The OTC is over 5 years away and Somaxon cant survive that long with the this group calling the signals.
 


















Top Bottom
Back
Quote